Research Comparison
5-Amino-1MQ vs Semaglutide
A side-by-side research comparison of 5-Amino-1MQ and Semaglutide drawn from Cobalt Peptides' peptide database records.
5-Amino-1MQ
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), developed for metabolic and longevity-focused research. By targeting a key regulatory enzyme involved in NAD+ metabolism, it has been investigated for its ability to enhance cellular energy production and mitochondrial efficiency. The compound is primarily explored in the context of metabolic health, body composition, and age-related cellular decline. Preclinical research suggests that modulation of NNMT activity may influence adiposity, insulin sensitivity, and mitochondrial biogenesis, making it of interest in both obesity and longevity research domains.
Semaglutide
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is acylated with a C18 fatty diacid through a γ-glutamyl spacer, which promotes albumin binding and extends its half-life to approximately seven days. The published literature describes GLP-1 receptor activation with downstream effects on insulin secretion, glucagon suppression and gastric emptying. Licensed medicines containing semaglutide exist and are prescribed by clinicians; the material supplied here is a research compound and is not one of them.